Essay --

Mid Term Assignment - GenzymeHIMP6170 Professor Aditya PaiShweta Harwalkar (ID 212294831)2/13/2014 Company / portfolio for analysis (Refer to vermiform appendix 1, 2, 3 & 4)Genzyme Corporation (Genzyme), a subsidiary of Sanofi-aventis, is a biotechnology company which is principally engaged in developing products and services for rare genetic disorders. The company has its operations oecumenical with its principal concentration in the US and the UK. Genzyme is headquartered in Massachusetts, the US. The parent company, Sanofi, is a global and diversified healthcare draw. Genzyme is currently organized into two job units Rare Diseases and octuple Sclerosis.Rare Diseases Focusing on uncommon and underserved medical examination conditions, the Rare Disease business unit is currently focused on three medical areasGenetic Diseases - Pioneering Solutions to Lysosomal Storage Disorders Orphan drugsEndocrinology - genetically engineered displacement of thyroid-stimulating hormone (TSH)Cardiovascular Disease - inherited disorders, such as familial hypercholesterolemia, a genetic and potentially life-threatening form of severely graduate(prenominal) cholesterol that often doesnt respond to traditional treatmentsMultiple sclerosis Multiple sclerosis is a chronic disease that affects each person differently, with symptoms ranging from unemotionality in the limbs or forgetfulness to paralysis or loss of vision. Revenues and growth trends(Refer to Appendix 5)Sanofi acquired Genzyme for $20.1 billion. New Genzyme was successfully integrated resulting in sales growth of 16.9%. gross revenue for Fabrazyme (agalsidase beta), a treatment for Fabry disease, nearly doubled. Sales for Myozyme and Lumizyme (alglucosidase alfa), indicated in Pompe d... ...better compensationsShareholdersA leader in orphan drug market ordain attract more than shareholdersGenzyme must increase economic value created for shareholdersRetail Chains bring down the retail chain can help Genz yme sell at unhorse price or have higher profitChanges in the retail chain system will probably affect the profit rim of the drug regimeWork closely with the government to make received that the orphan drugs are available in that country/marketGovernment regulates the price of drugs - If Genzyme does not lower the cost of orphan drugs, then it is precise likely that government will set a lower price, which will cut Genzymes profitOther rare disease associations leave effectively and work closely with these rare disease associationsMost rare diseases do not have treatment available - High determine will prevent some patients from getting treatment